First new motion sickness drug arrives after nearly half a century

FDA’s first new motion sickness drug in decades may matter more for GLP-1 side effects

The FDA’s Dec. 30 approval of Vanda Pharmaceuticals’ Nereus (tradipitant) adds a rare new option to a category that has leaned for decades on older anticholinergics and antihistamines, including the scopolamine patch and over-the-counter products such as meclizine and dimenhydrinate. In reporting on the decision, Reuters noted the approval as the first new FDA-cleared treatment… The post FDA’s first new motion sickness drug in decades may matter…

FDA Approves Tradipitant for Prevention of Vomiting From Motion Sickness

FDA approves tradipitant, a treatment for motion sickness, offering effective prevention after 40 years without new options.

FDA Approves Nereus by Vanda Pharmaceuticals as First Motion Sickness Drug in Decades

The U.S. Food and Drug Administration (FDA) has approve […] The post FDA Approves Nereus by Vanda Pharmaceuticals as First Motion Sickness Drug in Decades first appeared on GeneOnline News. The post FDA Approves Nereus by Vanda Pharmaceuticals as First Motion Sickness Drug in Decades appeared first on GeneOnline News.

Tradipitant Becomes First Treatment Approved for Vomiting Due to Motion Sickness in 4 Decades

Tradipitant, a novel NK-1 receptor antagonist, was proven effective at reducing the incidence and severity of nausea and vomiting in individuals with motion sickness.

First new motion sickness drug arrives after nearly half a century

Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration (FDA) approving a novel oral pill that helps prevent motion-induced vomiting – the first of its kind in more than 40 years.Continue ReadingCategory: Illnesses and conditions, Body and MindTags: FDA, Motion, Chronic illness, clinical trials, Drugs, Pharmaceuticals